166 related articles for article (PubMed ID: 23722880)
1. Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.
Stelter L; Fuchs S; Jungbluth AA; Ritter G; Longo VA; Zanzonico P; Raschzok N; Sauer IM; Bomalaski JS; Larson SM
Mol Imaging Biol; 2013 Dec; 15(6):768-75. PubMed ID: 23722880
[TBL] [Abstract][Full Text] [Related]
2. Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.
Stelter L; Evans MJ; Jungbluth AA; Zanzonico P; Ritter G; Ku T; Rosenfeld E; Bomalaski JS; Old L; Larson SM
J Nucl Med; 2012 Feb; 53(2):281-6. PubMed ID: 22228793
[TBL] [Abstract][Full Text] [Related]
3. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
[TBL] [Abstract][Full Text] [Related]
4. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
[TBL] [Abstract][Full Text] [Related]
5. [(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells.
Zhang CC; Yan Z; Li W; Kuszpit K; Painter CL; Zhang Q; Lappin PB; Nichols T; Lira ME; Affolter T; Fahey NR; Cullinane C; Spilker M; Zasadny K; O'Brien P; Buckman D; Wong A; Christensen JG
Clin Cancer Res; 2012 Mar; 18(5):1303-12. PubMed ID: 22170262
[TBL] [Abstract][Full Text] [Related]
6. Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.
Lee SJ; Kang HY; Kim SY; Chung JH; Oh SJ; Ryu JS; Kim SB; Kang JS; Park SK; Kim HM; Kim MH; Moon DH
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1436-48. PubMed ID: 21484374
[TBL] [Abstract][Full Text] [Related]
7. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
[TBL] [Abstract][Full Text] [Related]
8. [18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.
Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
PLoS One; 2012; 7(11):e50618. PubMed ID: 23226334
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901.
Leyton J; Smith G; Lees M; Perumal M; Nguyen QD; Aigbirhio FI; Golovko O; He Q; Workman P; Aboagye EO
Mol Cancer Ther; 2008 Sep; 7(9):3112-21. PubMed ID: 18790789
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
11. Increase of [(18)F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography.
Viertl D; Bischof Delaloye A; Lanz B; Poitry-Yamate C; Gruetter R; Mlynarik V; Ametamey SM; Ross TL; Lehr HA; André PA; Perillo-Adamer F; Kosinski M; Dupertuis YM; Buchegger F
Mol Imaging Biol; 2011 Apr; 13(2):321-31. PubMed ID: 20556524
[TBL] [Abstract][Full Text] [Related]
12. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
[TBL] [Abstract][Full Text] [Related]
13. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.
Wagner M; Seitz U; Buck A; Neumaier B; Schultheiss S; Bangerter M; Bommer M; Leithäuser F; Wawra E; Munzert G; Reske SN
Cancer Res; 2003 May; 63(10):2681-7. PubMed ID: 12750297
[TBL] [Abstract][Full Text] [Related]
14. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model.
Paproski RJ; Wuest M; Jans HS; Graham K; Gati WP; McQuarrie S; McEwan A; Mercer J; Young JD; Cass CE
J Nucl Med; 2010 Sep; 51(9):1447-55. PubMed ID: 20720035
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
[TBL] [Abstract][Full Text] [Related]
17. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.
Stelter L; Evans MJ; Jungbluth AA; Longo VA; Zanzonico P; Ritter G; Bomalaski JS; Old L; Larson SM
Mol Imaging; 2013; 12(1):67-73. PubMed ID: 23348793
[TBL] [Abstract][Full Text] [Related]
18. Sex as a Biologic Variable in Preclinical Imaging Research: Initial Observations with
Chan SR; Salem K; Jeffery J; Powers GL; Yan Y; Shoghi KI; Mahajan AM; Fowler AM
J Nucl Med; 2018 May; 59(5):833-838. PubMed ID: 29217733
[TBL] [Abstract][Full Text] [Related]
19. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
Tsai WB; Aiba I; Long Y; Lin HK; Feun L; Savaraj N; Kuo MT
Cancer Res; 2012 May; 72(10):2622-33. PubMed ID: 22461507
[TBL] [Abstract][Full Text] [Related]
20. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]